Post by Advanced Prostate Cancer Consensus Conference

New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study https://lnkd.in/eJYEjB2r In an international registry study of 11,154 patients, investigators developed PPP3 nomograms integrating clinical features and PSMA-PET PROMISE metrics to predict 3-, 5-, and 7-year overall survival in #ProstateCancer Developed and validated across 35 global sites, ✅ Models demonstrated strong discrimination (C-index ~0.83–0.84). ✅PPP3 performed as well as or better than existing clinical risk scores, supporting PSMA-PET–based risk stratification for guidelines, clinical decision-making, and trial design.  Caner Civan PD Dr. med. Isabel Rauscher Osman Güven  Matthias Eiber Sebastian Hoberück Matthias Miederer  Ralph A. Bundschuh Tobias Hölscher  Jeremie Calais  Constantin Lapa Andrea Farolfi Alexander Drzezga Jolanta Kunikowska Göksel Alçın Mohd Fazrin Mohd Rohani Claudia Kesch Ken Herrmann Andrei Gafita Michael Hofman Karolien Goffin Daniele Pizzuto Timo Soeterik  Halil Kömek Louise Emmett Andrej Vondrak  Francesco Lanfranchi  Matteo Bauckneht  Lena Unterrainer Anders Bjartell  Elin Trägårdh Marcin Miszczyk Prof. Dr. Martin Bögemann, FEBU Kambiz Rahbar Boris Hadaschik Wolfgang Fendler